A Phase 1 interventional study of Bevacizumab and Cetuximab in Advanced Malignant Neoplasm, Castleman Disease and Digestive System Carcinoma, sponsored by M.D. Anderson Cancer Center. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment
Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Adv…PubMed 26933802 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Castleman Disease with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Castleman Disease · United States.
Among the 14 studies in Castleman Disease with a site in United States, this one is the only one that started in 2012, is one of 5 in phase 1, and was the 5th registered.
22 studies on the registry are indexed under Castleman Disease; 9 are open to participants now.
Browse Castleman Disease studies →4 of the 14 studies in Castleman Disease with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18–80
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Castleman Disease studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 14 across 11 interventional studies indexed under Castleman Disease.
Median enrollment 14 across the 9 interventional studies, 280 across the 5 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 1 study filed under Castleman Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Castleman Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02817997University of PennsylvaniaInternational Registry for Patients With Castleman Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Castleman Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab.
SECONDARY OBJECTIVES:
I. Preliminary descriptive assessment of anti-tumor efficacy of each combination.
II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional).
OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups.
GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22.
GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21.
GROUP III: Patients receive temsirolimus and bevacizumab as in Group I.
In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Bevacizumab · Biological: Cetuximab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus
Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Bevacizumab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus · Drug: Valproic Acid
Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Bevacizumab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus
Given IV
Also known as: Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF
Given IV
Also known as: Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225
Optional correlative studies
Optional correlative studies
Given IV
Also known as: CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
Given PO
Also known as: Depakene, Stavzor, Valproate
Number of Participants With Dose Limiting Toxicities (DLT)
A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria: * Grade 3 or 4 non-hematologic toxicity (except nausea and vomiting responsive to appropriate regimens or alopecia) * Any Grade 4 hematologic toxicity lasting \> 14 days despite supportive measures * Any Grade 4 nausea or vomiting \> 5 days despite maximum anti-nausea regimens * Any other Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome * Any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy Note: correctable electrolyte imbalances and alopecia are not considered DLTs.
Time frame: First 28-day cycle
| Milestone | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/ MTD Expansion | Arm3/Ovarian Expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 16 | 2 | 3 | 6 | 4 | 3 | 6 | 6 | 3 | 3 | 7 | 6 | 3 | 4 | 3 | 4 | 3 | 6 | 3 | 4 | 10 | 8 |
| Completed | 3 | 16 | 2 | 3 | 6 | 4 | 3 | 6 | 6 | 3 | 3 | 7 | 6 | 3 | 4 | 3 | 4 | 3 | 6 | 3 | 4 | 10 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria: * Grade 3 or 4 non-hematologic toxicity (except nausea and vomiting responsive to appropriate regimens or alopecia) * Any Grade 4 hematologic toxicity lasting \> 14 days despite supportive measures * Any Grade 4 nausea or vomiting \> 5 days despite maximum anti-nausea regimens * Any other Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome * Any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy Note: correctable electrolyte imbalances and alopecia are not considered DLTs.
| Participants | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/ MTD Expansion | Arm3/Ovarian Expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLT) | 0 | 3 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 |
Collected over 13.5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm1/ Escalation Dose Level 1 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm1/ Escalation Dose Level 2 | 0/16 (0%) | 5/16 (31.3%) | 16/16 (100%) |
| Arm1/ Escalation Dose Level 3 | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Arm2/Escalation Dose Level 1 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Arm2/Escalation Dose Level 2 | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Arm2/Escalation Dose Level 3 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Arm2/Escalation Dose Level 4 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Arm2/Escalation Dose Level 5 | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Arm2/Escalation Dose Level 6 | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Arm2/Escalation Dose Level 7 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Arm2/Escalation Dose Level 8 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm2/Escalation Dose Level 9 | 0/7 (0%) | 6/7 (85.7%) | 7/7 (100%) |
| Arm2/Escalation Dose Level 10 | 1/6 (16.7%) | 4/6 (66.7%) | 5/5 (100%) |
| Arm3/Escalation Dose Level 1 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Arm3/Escalation Dose Level 2 | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| Arm3/Escalation Dose Level 3 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm3/Escalation Dose Level 4 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Arm3/Escalation Dose Level 5 | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Arm3/Escalation Dose Level 6 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Arm3/Escalation Dose Level 7 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm3/Escalation Dose Level 8 | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Arm3/Escalation MTD Expansion | 3/10 (30%) | 3/10 (30%) | 10/10 (100%) |
| Arm3/Ovarian Expansion | 0/8 (0%) | 3/8 (37.5%) | 7/8 (87.5%) |
| Event | Arm1/ Escalation Dose Level 1 | Arm1/ Escalation Dose Level 2 | Arm1/ Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation MTD Expansion | Arm3/Ovarian Expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/3 | 0/16 | 0/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 2/3 | 1/7 | 0/6 | — | 1/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 1/4 | 0/10 | 0/8 |
| PneumoniaInfections and infestations | 0/3 | 0/16 | 0/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 1/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 2/3 | 0/4 | 1/10 | 0/8 |
| HeadacheNervous system disorders | 0/3 | 0/16 | 1/2 | 0/3 | 0/6 | 0/4 | 1/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 1/4 | 0/3 | — | 0/3 | 1/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| MucositisGastrointestinal disorders | 0/3 | 0/16 | 1/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| HypertensionVascular disorders | 0/3 | 0/16 | 1/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| RashSkin and subcutaneous tissue disorders | 0/3 | 0/16 | 1/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| Wound dehiscenceSkin and subcutaneous tissue disorders | 1/3 | 0/16 | 0/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| Right preseptal orbital abscessInfections and infestations | 1/3 | 0/16 | 0/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| ANC decreasedInvestigations | 1/3 | 0/16 | 0/2 | 0/3 | 0/6 | 0/4 | 0/3 | 0/6 | 0/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 0/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 0/8 |
| FeverInfections and infestations | 1/3 | 0/16 | 0/2 | 0/3 | 1/6 | 0/4 | 0/3 | 0/6 | 1/6 | — | 0/3 | 0/7 | 0/6 | — | 0/4 | 1/3 | — | 0/3 | 0/6 | 0/3 | 0/4 | 0/10 | 1/8 |
| Event | Arm1/ Escalation Dose Level 1 | Arm1/ Escalation Dose Level 2 | Arm1/ Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation MTD Expansion | Arm3/Ovarian Expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HypertriglyceridemiaMetabolism and nutrition disorders | 3/3 | 11/16 | 1/2 | 3/3 | 5/6 | 2/4 | 3/3 | 2/6 | 3/6 | 2/3 | 1/3 | 2/7 | 3/5 | 2/3 | 1/4 | 0/3 | 2/4 | 0/3 | 2/6 | 1/3 | 2/4 | 7/10 | 2/8 |
| FatigueGeneral disorders | 2/3 | 8/16 | 2/2 | 0/3 | 4/6 | 1/4 | 1/3 | 1/6 | 1/6 | 1/3 | 0/3 | 1/7 | 4/5 | 2/3 | 2/4 | 1/3 | 3/4 | 2/3 | 6/6 | 2/3 | 3/4 | 8/10 | 4/8 |
| AnemiaBlood and lymphatic system disorders | 3/3 | 14/16 | 2/2 | 1/3 | 3/6 | 3/4 | 1/3 | 3/6 | 2/6 | 1/3 | 2/3 | 0/7 | 0/5 | 0/3 | 0/4 | 0/3 | 0/4 | 0/3 | 0/6 | 1/3 | 2/4 | 2/10 | 2/8 |
| AST elevationInvestigations | 3/3 | 9/16 | 0/2 | 3/3 | 3/6 | 3/4 | 1/3 | 2/6 | 1/6 | 1/3 | 1/3 | 0/7 | 1/5 | 0/3 | 0/4 | 1/3 | 1/4 | 0/3 | 0/6 | 1/3 | 2/4 | 4/10 | 3/8 |
| ThrombocytopeniaInvestigations | 0/3 | 3/16 | 2/2 | 1/3 | 3/6 | 3/4 | 0/3 | 5/6 | 6/6 | 3/3 | 3/3 | 2/7 | 3/5 | 2/3 | 0/4 | 2/3 | 1/4 | 0/3 | 3/6 | 1/3 | 3/4 | 4/10 | 2/8 |
| HyperglycemiaMetabolism and nutrition disorders | 3/3 | 11/16 | 1/2 | 2/3 | 4/6 | 2/4 | 0/3 | 1/6 | 2/6 | 2/3 | 1/3 | 1/7 | 3/5 | 0/3 | 0/4 | 0/3 | 0/4 | 0/3 | 2/6 | 1/3 | 2/4 | 2/10 | 2/8 |
| HyperkalemiaMetabolism and nutrition disorders | 1/3 | 3/16 | 2/2 | 1/3 | 0/6 | 1/4 | 0/3 | 1/6 | 1/6 | 1/3 | 0/3 | 0/7 | 0/5 | 0/3 | 0/4 | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/4 | 1/10 | 0/8 |
| HypercholesterolemiaMetabolism and nutrition disorders | 2/3 | 9/16 | 0/2 | 3/3 | 4/6 | 3/4 | 2/3 | 3/6 | 4/6 | 2/3 | 1/3 | 1/7 | 4/5 | 1/3 | 1/4 | 0/3 | 2/4 | 0/3 | 1/6 | 1/3 | 1/4 | 5/10 | 1/8 |
| NauseaGastrointestinal disorders | 1/3 | 3/16 | 2/2 | 1/3 | 3/6 | 4/4 | 0/3 | 2/6 | 2/6 | 0/3 | 1/3 | 0/7 | 1/5 | 1/3 | 1/4 | 0/3 | 1/4 | 2/3 | 3/6 | 1/3 | 1/4 | 3/10 | 3/8 |
| AnorexiaGeneral disorders | 0/3 | 2/16 | 2/2 | 0/3 | 4/6 | 2/4 | 0/3 | 3/6 | 3/6 | 0/3 | 0/3 | 3/7 | 2/5 | 1/3 | 1/4 | 0/3 | 1/4 | 1/3 | 0/6 | 0/3 | 1/4 | 0/10 | 1/8 |
| Age, Categorical(Participants) | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation Dose Level 9 | Arm3/Escalation Dose Level 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 12 | 2 | 3 | 5 | 4 | 2 | 5 | 4 | 1 | 1 | 4 | 6 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 3 | 6 | 5 | 83 |
| >=65 years | 1 | 4 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 2 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 4 | 1 | 1 | 4 | 3 | 33 |
| Sex: Female, Male(Participants) | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation Dose Level 9 | Arm3/Escalation Dose Level 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 5 | 1 | 1 | 3 | 2 | 3 | 3 | 2 | 0 | 2 | 5 | 4 | 1 | 3 | 3 | 2 | 1 | 3 | 1 | 1 | 9 | 8 | 65 |
| Male | 1 | 11 | 1 | 2 | 3 | 2 | 0 | 3 | 4 | 3 | 1 | 2 | 2 | 2 | 1 | 0 | 2 | 2 | 3 | 2 | 3 | 1 | 0 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation Dose Level 9 | Arm3/Escalation Dose Level 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 0 | 1 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 14 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 5 | 3 | 3 | 5 | 6 | 1 | 0 | 2 | 3 | 0 | 1 | 0 | 1 | 5 | 8 | 48 |
| Unknown or Not Reported | 3 | 12 | 2 | 2 | 3 | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 1 | 3 | 5 | 3 | 3 | 4 | 0 | 54 |
| Race (NIH/OMB)(Participants) | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation Dose Level 9 | Arm3/Escalation Dose Level 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 12 |
| White | 3 | 9 | 2 | 2 | 2 | 3 | 1 | 5 | 5 | 3 | 3 | 6 | 4 | 2 | 2 | 2 | 2 | 2 | 5 | 3 | 3 | 7 | 6 | 82 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 4 | 0 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 12 |
| Region of Enrollment(participants) | Arm1/Escalation Dose Level 1 | Arm1/Escalation Dose Level 2 | Arm1/Escalation Dose Level 3 | Arm2/Escalation Dose Level 1 | Arm2/Escalation Dose Level 2 | Arm2/Escalation Dose Level 3 | Arm2/Escalation Dose Level 4 | Arm2/Escalation Dose Level 5 | Arm2/Escalation Dose Level 6 | Arm2/Escalation Dose Level 7 | Arm2/Escalation Dose Level 8 | Arm2/Escalation Dose Level 9 | Arm2/Escalation Dose Level 10 | Arm3/Escalation Dose Level 1 | Arm3/Escalation Dose Level 2 | Arm3/Escalation Dose Level 3 | Arm3/Escalation Dose Level 4 | Arm3/Escalation Dose Level 5 | Arm3/Escalation Dose Level 6 | Arm3/Escalation Dose Level 7 | Arm3/Escalation Dose Level 8 | Arm3/Escalation Dose Level 9 | Arm3/Escalation Dose Level 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 3 | 16 | 2 | 3 | 6 | 4 | 3 | 6 | 6 | 3 | 3 | 7 | 6 | 3 | 4 | 3 | 4 | 3 | 6 | 3 | 4 | 10 | 8 | 116 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2012 to primary completion in May 2026, 162 months.
Results were first posted in Nov 2026, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Adv…PubMed 26933802 ↗
Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Adv…PubMed 26933802 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Temsirolimus